The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

MMRGlobal Receives Additional Biotech Patent Protection in US, Mexico and Japan for Cancer Vaccines

03-Oct-2013 | Source : AG-IP News | Visits : 6037
LOS ANGELES, CA - MMRGlobal Inc. today announced in a press release that two additional patents will be granted for its B-cell vaccine technologies. MMR has been notified it will receive another US patent protecting methods of making compositions for B-cell vaccines pursuant to a Notice of Allowance from the United States Patent and Trademark Office. The patent, US Serial No. 3/293,495 entitled "Method and Composition for Altering a B-cell Mediated Pathology," will represent the fourth US manufacturing patent that covers the methods of making compositions for B-cell vaccines used in the fight against lymphoma and potentially other forms of cancer. Earlier this month, MMR also received a Notice of Allowance in Mexico for protecting the same technology, Mexico Serial No. MX/a/2012/009182 entitled "Method and Composition for Altering a B-cell Mediated Pathology." This will be the third issued patent in Mexico to protect this technology.

Also earlier this month, MMR filed a divisional application involving similar technology in an effort to retain another pending application in Japan. The additional patent application has been filed with the Japanese Patent Office to introduce 26 additional patent claims under Patent Application No. 2013 -186384 protecting "Altering a B Cell Pathology Using Self-Derived Antigens in Conjunction with Specific-Binding Cytoreductive Agent." Additional patent applications are also pending in Japan.

MMR's strategy of filing continuing patent applications in countries of commercial interest like Japan allows the Company to take advantage of an international treaty to expedite receiving patents based on existing approvals in the US.

Prior to the Company's reverse merger in 2009 with San Diego-based biotechnology company, Favrille, Inc., originally spun off from the Sidney Kimmel Cancer Center, Favrille had invested more than $100 million in research and development on its FavId™ vaccine trials and use of customized tumor cells to treat lymphoma patients and other technologies. MMR has continued to make progress in protecting its biotech IP, including its anti-CD20 antibodies, and the other B-Cell vaccine patents entitled "Method and Composition for Altering a B-Cell Mediated Pathology."

Although MMRGlobal will continue working to license and otherwise exploit an extensive portfolio of biotech assets, including its anti-CD20 monoclonal antibodies, and additionally, data from vaccine trials, thousands of patient tumor samples and other intellectual property including numerous worldwide patents in various stages, it remains focused on its primary health IT business. MMR has numerous patents issued or pending related to providing online medical and Personal Health Records in more than 12 countries of commercial interest and has hundreds of additional claims either pending or published related to health information technology in the US and other parts of the world.

MMRGlobal Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet.
share



Related Articles